Initially, the drug was made for the treatment of malignant tumors. The study of the drug's effect on the coronavirus took place in a test tube on tissues and in rodents.
Histopathological analysis showed a decrease in pneumonia in mice treated with Plytidepsin compared to mice treated with Remdesivir already on the third day after infection.
The study authors recommend conducting more extensive clinical studies on the use of Plytidepsin for the treatment of COVID-19.
This publication was prepared in collaboration with the laboratories of the Mount Sinai Medical Center (New York), the University of California at San Francisco and the Pasteur Institute (Paris).


Be Civil, No Spam!!!